These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 30082106)
1. Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents. Li Z; Xu X; Liu R; Deng F; Zeng X; Zhang L Bioorg Med Chem; 2018 Aug; 26(15):4560-4566. PubMed ID: 30082106 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Li Z; Xu X; Deng L; Liao R; Liang R; Zhang B; Zhang L Bioorg Med Chem; 2018 Aug; 26(14):3947-3952. PubMed ID: 29954682 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of phenylfuroxan nitric oxide-donor phenols as potential anti-diabetic agents. Xie YD; Shao LH; Wang QT; Bai Y; Li N; Yang G; Li YP; Bian XL Bioorg Chem; 2019 Aug; 89():103000. PubMed ID: 31132604 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents. Xie Y; Shao L; Wang Q; Bai Y; Chen Z; Li N; Xu Y; Li Y; Yang G; Bian X Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3731-3735. PubMed ID: 30343953 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1. Yang J; Gu E; Yan T; Shen D; Feng B; Tang C Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112 [TBL] [Abstract][Full Text] [Related]
9. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold. Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents. Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold. Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813 [TBL] [Abstract][Full Text] [Related]
12. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes. Zhou Y; Wang Y; Zhang L; Tang C; Feng B Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769 [TBL] [Abstract][Full Text] [Related]
13. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092 [TBL] [Abstract][Full Text] [Related]
14. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835. Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825 [TBL] [Abstract][Full Text] [Related]
15. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. Li Z; Liu C; Shi W; Cai X; Dai Y; Liao C; Huang W; Qian H Bioorg Med Chem; 2018 Feb; 26(3):703-711. PubMed ID: 29291938 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294 [TBL] [Abstract][Full Text] [Related]
18. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice. Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine. Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095 [TBL] [Abstract][Full Text] [Related]
20. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]